Stockscreener 앱 받기
9.00
0.90%
0.08
시간 외 거래:
9.00
전일 마감가:
$8.92
열려 있는:
$8.8
하루 거래량:
752.74K
Relative Volume:
2.53
시가총액:
$606.31M
수익:
$568.09M
순이익/손실:
$27.27M
주가수익비율:
27.47
EPS:
0.3276
순현금흐름:
$71.41M
1주 성능:
+4.65%
1개월 성능:
+4.90%
6개월 성능:
+29.87%
1년 성능:
-9.37%
1일 변동 폭
$8.77
$9.155
1주일 범위
$8.555
$9.155
52주 변동 폭
$5.81
$10.13
Bioventus Inc Stock (BVS) Company Profile
명칭
Bioventus Inc
전화
(919) 474-6700
주소
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
9.00 | 600.92M | 568.09M | 27.27M | 71.41M | 0.3276 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 개시 | Barrington Research | Outperform |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-07 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2022-11-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-11-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 개시 | Craig Hallum | Buy |
| 2021-11-15 | 재개 | Morgan Stanley | Overweight |
| 2021-11-10 | 재개 | JP Morgan | Overweight |
| 2021-07-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-08 | 개시 | Canaccord Genuity | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | JP Morgan | Overweight |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioventus Inc 주식(BVS)의 최신 뉴스
Barrington Research initiates coverage of Bioventus (BVS) with outperform recommendation - MSN
Does Bioventus Inc have a competitive edge2026 Buyback Activity & Growth Focused Stock Pick Reports - baoquankhu1.vn
Bioventus (BVS) CFO receives major stock awards and exercises RSUs - Stock Titan
Bioventus (BVS) SVP granted RSUs, options and exercises prior awards - Stock Titan
Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards - Stock Titan
Bioventus (BVS) CEO adds major RSU and option grants, exercises awards - Stock Titan
Travel Stocks: Is Bioventus Inc attractive for institutional investors2026 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Bioventus : Corporate PresentationMarch 2026 - marketscreener.com
Divisadero Street Capital Management LP Sells 385,116 Shares of Bioventus Inc. $BVS - MarketBeat
Insider Sell: Michelle Mcmurry-heath Sells 12,000 Shares of Biov - GuruFocus
Bioventus (NASDAQ:BVS) Director Michelle Mcmurry-Heath Sells 12,000 Shares - MarketBeat
Bioventus (BVS) director logs open-market sale of 12,000 shares - Stock Titan
Bioventus (NASDAQ:BVS) Finds Fresh Attention In Nasdaq Today Sector - Kalkine Media
Bioventus Receives Consensus Buy Rating from Analysts - National Today
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - MSN
Bioventus stock delivers 63% return after Fair Value signal By Investing.com - Investing.com Australia
Bioventus stock delivers 63% return after Fair Value signal - Investing.com India
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence - GlobeNewswire Inc.
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges - Investing.com Nigeria
Bioventus Earnings Call Signals Profitable Growth Ahead - TipRanks
BVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bioventus Inc. (NASDAQ:BVS) Q4 2025 earnings call transcript - MSN
Momentum Shift: How is Bioventus Inc managing supply chain issues2026 Breakouts & Breakdowns & Stepwise Trade Signal Implementation - baoquankhu1.vn
Risks Report: Is Bioventus Inc exposed to currency risksJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Craig-Hallum Maintains Buy on Bioventus Inc (BVS) March 2026, PT $16 - Meyka
Aug Action: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Bioventus (NYSE:BVS) In Focus as NYSE Composite Tracks MedTech Moves - Kalkine Media
Bioventus (BVS) Receives Updated Price Target from Barrington Re - GuruFocus
Bioventus (NYSE:BVS) Stock Price Expected to Rise, Barrington Research Analyst Says - MarketBeat
Bioventus (NASDAQ:BVS) Shares Down 8.2%Here's Why - MarketBeat
Bioventus (NYSE:BVS) Given New $16.00 Price Target at Craig Hallum - MarketBeat
Craig-Hallum raises Bioventus stock price target on guidance beat By Investing.com - Investing.com India
Craig-Hallum raises Bioventus stock price target on guidance beat - Investing.com India
Barrington Adjusts Price Target on Bioventus to $14 From $13, Maintains Outperform Rating - marketscreener.com
Bioventus Inc. (NASDAQ:BVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Bioventus: Q4 Earnings Snapshot - theheraldreview.com
Bioventus Q4 Earnings Assessment - Sahm
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Australia
BVS Targets Revenue Range of $600M-$610M for FY26 - GuruFocus
Bioventus Q4 Earnings Call Highlights - MarketBeat
Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Org - GuruFocus
Bioventus (NYSE:BVS) Shares Gap UpHere's Why - MarketBeat
Bioventus Shares Rise After Analyst Upgrade - National Today
Bioventus Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Bioventus Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
Bioventus (BVS) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges By Investing.com - Investing.com South Africa
Bioventus (NASDAQ:BVS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Bioventus Inc (BVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):